In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Boehringer Ingelheim licenses Medivir HIV candidate

Executive Summary

Medivir AB (develops drugs to suppress and regulate the function of proteases and polymerases in various medical disorders) licensed Boehringer Ingelheim Corp. exclusive worldwide marketing rights (excluding Sweden, Denmark, Finland, Norway, and Iceland where Medivir will retain rights) to MIV-310, its antiviral compound in Phase II to treat multi-drug resistant HIV.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies